Filters
Custom request?
Type
Production region
Qualifications
Country of origin
Tenoxicam API Manufacturers & Suppliers
5 verified results
Commercial-scale Suppliers
Employees: 50
All certificates
Employees: 700+
All certificates
All certificates
All certificates
All certificates
Total market transparency
Supplier trade data access
Buyer / supplier flow comparison
Tenoxicam | CAS No: 59804-37-4 | GMP-certified suppliers
A medication that provides anti-inflammatory and analgesic effects for managing rheumatoid arthritis, osteoarthritis, back pain, and acute musculoskeletal pain conditions.
Therapeutic categories
Primary indications
- For the treatment of rheumatoid arthritis, osteoarthritis, backache, and pain
Product Snapshot
- Tenoxicam is available in multiple formulation types including oral solid dosage forms (tablet, capsule), injectable forms (powder for solution, solution), and suppositories
- It is primarily indicated for the treatment of inflammatory and musculoskeletal conditions such as rheumatoid arthritis, osteoarthritis, backache, and general pain
- Tenoxicam is approved for use in the Canadian pharmaceutical market
Clinical Overview
Pharmacodynamically, tenoxicam exerts its effects by inhibiting the cyclooxygenase (COX) enzymes, which catalyze the conversion of arachidonic acid to prostaglandins. This inhibition reduces peripheral prostaglandin synthesis, thereby diminishing inflammation and pain by decreasing sensitization of peripheral nociceptors. The antipyretic effect is thought to result from a central action on the hypothalamic thermoregulatory center, leading to vasodilation and increased heat dissipation.
The mechanism of action is consistent with inhibition of both COX-1 and COX-2 isoenzymes, categorizing tenoxicam as a non-selective NSAID. As a substrate of cytochrome P450 CYP2C9, its metabolism may be influenced by concomitant administration of CYP2C9 modulators, which should be considered in clinical settings.
Pharmacokinetic data relevant to formulation and safety include absorption, distribution, metabolism predominantly via hepatic pathways involving CYP2C9, and renal excretion. Tenoxicam’s long half-life supports once-daily dosing; however, detailed ADME parameters should be referenced from authoritative sources for precise formulation design.
Safety considerations include risks typical of non-selective NSAIDs: gastrointestinal irritation, risk of nephrotoxicity, potential for hypertension, and hyperkalemia. Caution is advised in patients with preexisting renal or cardiovascular conditions. Tenoxicam is identified as an OAT3 (organic anion transporter 3) inhibitor, which may influence drug disposition and interactions.
Globally, tenoxicam is approved and marketed under various brand names, predominantly in regions where oxicam agents are in use for musculoskeletal disorders. Regulatory dossiers emphasize stringent adherence to quality standards due to its narrow therapeutic index and potential adverse effects.
For API procurement, sourcing from manufacturers with validated compliance to international pharmacopeial standards and Good Manufacturing Practices (GMP) is critical. Batch-to-batch consistency, impurity profiles, and adequate stability data must be assured to support formulation development and regulatory submission. Analytical characterization should include confirmation of identity, purity, and absence of polymorphic variability to ensure reproducible clinical performance.
Identification & chemistry
| Generic name | Tenoxicam |
|---|---|
| Molecule type | Small molecule |
| CAS | 59804-37-4 |
| UNII | Z1R9N0A399 |
| DrugBank ID | DB00469 |
Pharmacology
| Summary | Tenoxicam is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase enzymes (COX-1 and COX-2), reducing prostaglandin synthesis. This inhibition mediates its anti-inflammatory, analgesic, and antipyretic effects by decreasing peripheral pain sensitization and modulating central thermoregulatory pathways. It is primarily used for managing inflammatory conditions and pain associated with rheumatoid arthritis and osteoarthritis. |
|---|---|
| Mechanism of action | The antiinflammatory effects of tenoxicam may result from the inhibition of the enzyme cycooxygenase and the subsequent peripheral inhibition of prostaglandin synthesis. As prostaglandins sensitize pain receptors, their inhibition accounts for the peripheral analgesic effects of tenoxicam. Antipyresis may occur by central action on the hypothalamus, resulting in peripheral dilation, increased cutaneous blood flow, and subsequent heat loss. |
| Pharmacodynamics | Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain. |
Targets
| Target | Organism | Actions |
|---|---|---|
| Prostaglandin G/H synthase 2 | Humans | inhibitor |
| Prostaglandin G/H synthase 1 | Humans | inhibitor |
ADME / PK
| Absorption | Oral absorption of tenoxicam is rapid and complete (absolute bioavailability 100%). |
|---|---|
| Half-life | 72 hours (range 59 to 74 hours) |
| Protein binding | 99% |
| Metabolism | Tenoxicam is metabolized in the liver to several pharmacologically inactive metabolites (mainly 5'-hydroxy-tenoxicam). |
Formulation & handling
- Tenoxicam is a small molecule alpha-amino acid derivative available for oral, parenteral, and rectal administration. Formulations include solid oral dosage forms, injectable solutions, and suppositories, with injectable forms often supplied as lyophilized powders for reconstitution. Oral administration should consider administration with food to reduce potential gastrointestinal irritation.
Regulatory status
| Lifecycle | The active pharmaceutical ingredient is currently marketed in Canada with patent protection expected to expire within the next 12 months, indicating an upcoming transition toward generic availability and increased market competition. |
|---|
| Markets | Canada |
|---|
Supply Chain
| Supply chain summary | The Tenoxicam supply landscape includes multiple originator companies marketing branded formulations, such as Mobiflex and Novo-tenoxicam, primarily within the Canadian market. Branded products appear localized, with limited presence in major markets like the US or EU. Patent expiry in this class suggests that generic competition is either established or imminent. |
|---|
Tenoxicam is a type of NSAIDs
NSAIDs (Non-Steroidal Anti-Inflammatory Drugs) are a widely used subcategory of pharmaceutical Active Pharmaceutical Ingredients (APIs). These medications are commonly prescribed for their analgesic (pain-relieving), anti-inflammatory, and antipyretic (fever-reducing) properties. NSAIDs work by inhibiting the production of certain enzymes called cyclooxygenases (COX), which play a crucial role in the synthesis of prostaglandins, substances that contribute to pain, inflammation, and fever.
These pharmaceutical APIs are available in various formulations, including tablets, capsules, creams, and gels, making them convenient for different administration routes. Some popular examples of NSAIDs include aspirin, ibuprofen, naproxen, and diclofenac.
NSAIDs are commonly used to treat a wide range of conditions such as arthritis, musculoskeletal injuries, dental pain, menstrual pain, and headaches. They are also effective in managing inflammatory conditions like rheumatoid arthritis and ankylosing spondylitis.
While NSAIDs are generally safe and effective when used as directed, they may have side effects. These can include gastrointestinal issues such as stomach ulcers or bleeding, cardiovascular risks, and kidney problems. Therefore, it is essential to follow the recommended dosage and consult with healthcare professionals to ensure proper and safe usage.
In conclusion, NSAIDs are a subcategory of pharmaceutical APIs that offer analgesic, anti-inflammatory, and antipyretic properties. Their versatility and effectiveness in treating various conditions make them widely prescribed medications. However, it is crucial to be aware of potential side effects and consult healthcare providers for appropriate usage.
Tenoxicam (NSAIDs), classified under Anti-inflammatory Agents
Anti-inflammatory agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used to treat various inflammatory conditions. These agents play a vital role in alleviating pain, reducing swelling, and controlling inflammation in the body. They are widely employed in the management of diverse medical conditions, including arthritis, autoimmune disorders, asthma, and skin conditions like dermatitis.
Anti-inflammatory APIs primarily function by inhibiting the production of specific enzymes called cyclooxygenases (COX) and lipoxygenases (LOX). These enzymes are responsible for the synthesis of pro-inflammatory molecules known as prostaglandins and leukotrienes, respectively. By suppressing the activity of COX and LOX, anti-inflammatory agents effectively curtail the production of these inflammatory mediators, thereby mitigating inflammation.
Common examples of anti-inflammatory APIs include non-steroidal anti-inflammatory drugs (NSAIDs) like ibuprofen, aspirin, and naproxen. These agents exhibit analgesic, antipyretic, and anti-inflammatory properties. Another group of anti-inflammatory APIs includes corticosteroids, such as prednisone and dexamethasone, which are synthetic hormones that modulate the body's immune response to control inflammation.
In conclusion, anti-inflammatory agents are a vital category of pharmaceutical APIs widely used to manage inflammation-related disorders. They target enzymes involved in the synthesis of pro-inflammatory molecules, effectively reducing pain and swelling. NSAIDs and corticosteroids are commonly prescribed anti-inflammatory APIs due to their efficacy in controlling inflammation.
Tenoxicam API manufacturers & distributors
Compare qualified Tenoxicam API suppliers worldwide. We currently have 5 companies offering Tenoxicam API, with manufacturing taking place in 3 different countries. Use the table below to review supplier type, countries of origin, certifications, product portfolio and GMP audit availability.
| Supplier | Type | Country | Product origin | Certifications | Portfolio |
|---|---|---|---|---|---|
| AXXO GmbH | Distributor | Germany | European Union | CEP, CoA, GMP, GDP, MSDS, USDMF | 243 products |
| Edmond Pharma (Recipharm) | Producer | Italy | Italy | CEP, CoA, FDA, GMP | 20 products |
| Nantong Jinghua | Producer | China | China | CoA, USDMF | 12 products |
| Solfyn International LLP | Distributor | India | China | CoA | 24 products |
| Zhejiang Hengkang Pharmac... | Producer | China | China | BSE/TSE, CEP, CoA, EDMF/ASMF, MSDS, USDMF, WC | 31 products |
When sending a request, specify which Tenoxicam API quality you need: for example EP (Ph. Eur.), USP, JP, BP, or another pharmacopoeial standard, as well as the required grade (base, salt, micronised, specific purity, etc.).
Use the list above to find high-quality Tenoxicam API suppliers. For example, you can select GMP, FDA or ISO certified suppliers. Visit our help page to learn more about sourcing APIs via Pharmaoffer.
